Licensing agreement between Laekna and Novartis

2018-01-08

On July 09th 2017 , Laekna acquired the global rights from Novartis Pharma AG to develop, manufacture and commercialize small molecule candidate LAE001 (previously known as CFG920) for prostate cancer. LAE001 has been previously studied in phase II clinical trial in the United States, and demonstrated satisfactory efficacy and safety profile in metastatic castration prostate cancer patients. Laekna are committed to deliver this drug further to regulatory approval in China and the rest of the world.

News Link：
http://www.chinabiotoday.com/articles/20170710

Last:$18.5 Million series A round of financing from Orbimed Asia and Anlongmed Fund

Next:none

Back

Media contact

e-mail:communication@laekna.com

Recommendation

2024-06-26

Laekna Announces First Subject Dosed in Phase I Clinical Trial of LAE102 (a monoclonal antibody against ActRIIA) in China for The Treatment of Obesity
More

RSS Feeds

If you want to know more about Laekna, please fill in the form below and sign up for emails: